Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions

被引：2

作者：

Zamarin, Dmitriy ^{[1
]}

Palese, Peter ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA

来源：

FUTURE MICROBIOLOGY | 2012年 / 7卷 / 03期

关键词：

apoptosis; cancer; immunotherapy; interferon; NDV; oncolytic; TUMOR-CELL VACCINE; EHRLICH ASCITES TUMOR; ACTIVE SPECIFIC IMMUNOTHERAPY; HEMAGGLUTININ-NEURAMINIDASE PROTEIN; BISPECIFIC FUSION PROTEIN; APOPTOSIS-INDUCING LIGAND; SELECTIVE GENE-TRANSFER; II MALIGNANT-MELANOMA; AVIAN INFLUENZA-VIRUS; COLORECTAL-CANCER;

D O I：

10.2217/FMB.12.4

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Newcastle disease virus (NDV) is an avian paramyxovirus, which has been demonstrated to possess significant oncolytic activity against mammalian cancers. This review summarizes the research leading to the elucidation of the mechanisms of NDV-mediated oncolysis, as well as the development of novel oncolytic agents through the use of genetic engineering. Clinical trials utilizing NDV strains and NDV-based autologous tumor cell vaccines will expand our knowledge of these novel anticancer strategies and will ultimately result in the successful use of the virus in the clinical setting.

引用

页码：347 / 367

页数：21

共 191 条

[1] CELLULAR CHANGES ASSOCIATED WITH INFECTION OF THE EHRLICH ASCITES TUMOR WITH NEWCASTLE DISEASE VIRUS [J].

ADAMS, WR ;

PRINCE, AM .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1959, 81 (01) :89-100

[2] Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer [J].

Ahlert, T ;

Sauerbrei, W ;

Bastert, G ;

Ruhland, S ;

Bartik, B ;

Simiantonaki, N ;

Schumacher, J ;

Hacker, B ;

Schumacher, M ;

Schirrmacher, V .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1354-1366

[3]

AHLERT T, 1990, CANCER RES, V50, P5962

[4] A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization [J].

Ahmed, A ;

Thompson, J ;

Emiliusen, L ;

Murphy, S ;

Beauchamp, RD ;

Suzuki, K ;

Alemany, R ;

Harrington, K ;

Vile, RG .

NATURE BIOTECHNOLOGY, 2003, 21 (07) :771-777

[5]

Alexander D. J., 1988, Newcastle disease., P1

[6] Cytolytic Effects and Apoptosis Induction of Newcastle Disease Virus Strain AF2240 on Anaplastic Astrocytoma Brain Tumor Cell Line [J].

Ali, Rola ;

Alabsi, Aied M. ;

Ali, Abdul Manaf ;

Ideris, Aini ;

Omar, Abdul Rahman ;

Yusoff, Khatijah ;

Saif-Ali, Riyadh .

NEUROCHEMICAL RESEARCH, 2011, 36 (11) :2051-2062

[7] Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma [J].

Altomonte, Jennifer ;

Marozin, Sabrina ;

Schmid, Roland M. ;

Ebert, Oliver .

MOLECULAR THERAPY, 2010, 18 (02) :275-284

[8] Cytoplasmic DNA innate immune pathways [J].

Barber, Glen N. .

IMMUNOLOGICAL REVIEWS, 2011, 243 :99-108

[9] Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells [J].

BarEli, N ;

Giloh, H ;

Schlesinger, M ;

ZakayRones, Z .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1996, 122 (07) :409-415

[10] A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire [J].

Batliwalla, FM ;

Bateman, BA ;

Serrano, D ;

Murray, D ;

Macphail, S ;

Maino, VC ;

Ansel, JC ;

Gregersen, PK ;

Armstrong, CA .

MOLECULAR MEDICINE, 1998, 4 (12) :783-794

← 1 2 3 4 5 6 7 8 9 10 →